Month: July 2024

Paves the Way for Kane’s revyve™ Antimicrobial Wound Gel Spray WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA) has eliminated its usage limitation on the Company’s 510(k) cleared revyve™ Antimicrobial Wound Gel (“revyve™”). Prior to the removal of this restriction, there was a 90 grams/month limit to the amount of revyve™ product that could be administered to patients. This now clears the way for the introduction and extended use of Kane’s revyve™ Antimicrobial Wound Gel Spray which is expected to be filled in spray cans in a higher quantity making it ideal for application on large wounds. “This is yet another important development for Kane as it allows...

MONTREAL, July 23, 2024 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier” or the “Company”) announced that it intends to vigorously defend itself against a class action which the Superior Court of Québec only partially authorized Plaintiff Jérôme Gauthier to institute against it (the “Authorization Decision”). Bombardier denies any wrongdoing. As previously disclosed, on April 21, 2023, an application for authorization to institute a class action was filed before the Superior Court of Québec, in the district of Montréal, against Bombardier and Messrs. Pierre Beaudoin, Éric Martel and Alain Bellemare (respectively, the Chairman of the Board of Directors, the President and Chief Executive Officer and the former President and Chief Executive Officer of Bombardier) (the “Application”). The Application...

GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of 2024, as well as full year guidance. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be accessed from the Investors page of Emergent’s website. About Emergent BioSolutionsAt...

Second Quarter 2024 HighlightsConsolidated net sales of $543.3 million, a decrease of 5% to the prior year, with lower sales across all three segments Operating income was $79.1 million with operating margin of 14.6% GAAP fully diluted earnings per share (EPS) was $1.26FORT WAYNE, Ind., July 23, 2024 (GLOBE NEWSWIRE) — Franklin Electric Co., Inc. today announced its second quarter financial results for fiscal year 2024. Second quarter 2024 net sales were $543.3 million, compared to second quarter 2023 net sales of $569.1 million. Second quarter 2024 operating income was $79.1 million, compared to second quarter 2023 operating income of $80.9 million. Second quarter 2024 EPS was $1.26, versus EPS in the second quarter 2023 of $1.27. “The Franklin team achieved solid results in the second quarter, marking one of the strongest...

EVANSVILLE, Ind., July 23, 2024 (GLOBE NEWSWIRE) — Old National Bancorp (NASDAQ: ONB) reports 2Q24 net income applicable to common shares of $117.2 million, diluted EPS of $0.37; $144.1 million and $0.46 on an adjusted1 basis, respectively. CEO COMMENTARY:“Old National’s second quarter results exceeded expectations due to better than expected revenue growth and lower expenses,” said Chairman and CEO Jim Ryan. “We achieved these outstanding results while also successfully closing on our CapStar Bank partnership and working to complete the associated systems integration. As a result, Old National has meaningfully increased our presence in Nashville, Tenn., while expanding our operations into several other vibrant Southeastern markets.”     SECOND QUARTER HIGHLIGHTS2:Net IncomeNet income applicable...

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information:Date:  Tuesday, August 6, 2024Time: 8:30 AM Eastern TimeUnited States: 1-877-300-8521International: 1-412-317-6026Israel: 1-80-921-2373Conference ID: 10190847Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1679332&tp_key=1f7beb24a2   The...

Addition of Premium Restorative Components Enhances ZimVie’s End-to-End Implant Offerings PALM BEACH GARDENS, Fla., July 23, 2024 (GLOBE NEWSWIRE) — ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio. The launch expands ZimVie’s portfolio of end-to-end prosthetic offerings and follows the recent receipt of FDA 510(k) clearance. ZimVie first launched the GenTek portfolio in Europe in 2019 and has seen tremendous success in that market to date. The introduction of GenTek to the U.S. market brings a broad offering of differentiated restorative components to the ZimVie product family. The GenTek restorative portfolio is comprised of Ti-Bases, pre-milled abutment blanks, screws, instruments, and ancillary products...

DALLAS, July 23, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added three new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: University Medical Center (UMC) Burn Center at Texas Tech University Health Sciences Center led by principal investigator Alan Pang, M.D., Tampa General Hospital Burn Center led by principal investigator Jared Troy, M.D., and University of South Alabama (USA) Health Emergency Department led by Andrew Bright, D.O. These new locations expand the total number of U.S. Clinical Trial Sites to 16, comprised of both burn centers and Emergency Departments (EDs). The 2024 U.S. Burn Pivotal Study is...